Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | PDE1A | P54750 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18885373 | 0.80 | CYP1A2 (0.36) | KDM4EPDE1APDE1BPDE1CCDK4 | |
| SCHEMBL15340919 | 0.80 | MAPK1 (0.32) | KDM4E | |
| SCHEMBL19542265 | 0.79 | PDE1A (0.34) | KDM4EPDE1APDE1BPDE1CCDK4 | |
| SCHEMBL29705402 | 0.79 | HSD17B10 (0.39) | KDM4EPDE1APDE1BPDE1CCDK4 | |
| SCHEMBL19966495 | 0.79 | HSD17B10 (0.39) | KDM4EPDE1APDE1BPDE1CCDK4 | |
| SCHEMBL22419377 | 0.77 | FGFR1 (0.36) | KDM4EPDE1APDE1BPDE1C | |
| SCHEMBL22419371 | 0.76 | PDE1A (0.38) | KDM4EPDE1APDE1BPDE1CCDK4 | |
| SCHEMBL18885367 | 0.72 | HCAR3 (0.35) | HCAR3 | |
| SCHEMBL1296332 | 0.72 | PDE1B (0.36) | PDE1APDE1BPDE1C | |
| SCHEMBL13677504 | 0.71 | KMO (0.41) | KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10363257-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-07-30 | — | — | US | disclosed |
| US-10010556-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-07-03 | — | — | US | disclosed |
| US-10010556-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-07-03 | — | — | US | disclosed |
| US-20180161337-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2018-06-14 | — | — | US | disclosed |
| US-20180161337-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2018-06-14 | — | — | US | disclosed |
| US-20170313722-A1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2017-11-02 | — | — | US | disclosed |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-08-03 | — | — | US | disclosed |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-08-03 | — | — | US | disclosed |
| US-9663520-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-9663520-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-9657033-B2 | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease | LYCERA CORPORATION (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657033-B2 | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease | LYCERA CORPORATION (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. | 2016-06-09 | — | — | US | disclosed |
| US-20150111877-A1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10363257-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | KDM4E 410/4885PDE1A 2697/4885PDE1B 2349/4885 |
| US-10010556-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | KDM4E 410/4885PDE1A 2697/4885PDE1B 2349/4885 |
| US-20180161337-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | KDM4E 367/4885PDE1A 2601/4885PDE1B 2332/4885 |
| US-20170313722-A1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORC, RORB, RORA | KDM4E 3553/4885PDE1A 2778/4885PDE1B 2626/4885 |
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | KDM4E 367/4885PDE1A 2601/4885PDE1B 2332/4885 |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | KDM4E 367/4885PDE1A 2601/4885PDE1B 2332/4885 |
| US-20150111877-A1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORC, RORB, RORA | KDM4E 3553/4885PDE1A 2778/4885PDE1B 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.